The aim of the present study is comparing the effectiveness of different treatment regimens for investigating the therapeutic potential for each one in management of Vaso-occlusive pain in pediatric sickle cell disease. In addition, investigators apply the Cost-effectiveness analysis (CEA) as a form of economic analysis that compares the relative costs and outcomes (effects) for different treatment regimens on vaso-occlusive painful crisis.
"Sickle cell disease is an inherited blood disorder characterized by defective hemoglobin (a protein in red blood cells that carries oxygen to the tissues of the body). Sickle cell disease involves the red blood cells, or hemoglobin, and their ability to carry oxygen. Normal hemoglobin cells are smooth, round, and flexible, like the letter "O," so they can move through the vessels in our bodies easily. Sickle cell hemoglobin cells are stiff and sticky and form into the shape of a sickle, or the letter "C," when they lose their oxygen. These sickle cells tend to cluster together and cannot easily move through the blood vessels. The cluster causes a blockage in small arteries or capillaries and stops the movement of healthy, normal oxygen-carrying blood. This blockage is what causes the painful and damaging complications of sickle cell disease". "Acute vaso-occlusive crisis (VOC) is a hallmark of sickle cell disease (SCD). Multiple complex pathophysiological processes can result in pain during a VOC. Despite significant improvements in the understanding and management of SCD, little progress has been made in the management of pain in SCD, although new treatments are being explored". The Painful Episodes: "The day-to-day management of sickle cell disease often equates with the management of acute and chronic pain. Patients manage many painful events at home so that hospital visits underestimate the frequency of pain Acute painful episodes are the most commonly encountered vaso-occlusive events in patients of all ages. Presumed to be caused by sickle vaso-occlusion, pain often starts in young children as the hand-foot syndrome or dactylitis, a painful swelling of hands and feet due to inflammation of the metacarpal and metatarsal periosteum. Painful episodes, which last from hours to many days, usually occur with little warning and a clear precipitating event is not often found.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
350
Omega-3 supplementation (300-400mg EPA \& 200-300mg DHA) per day for 8 consecutive months up to 10 months
50 patients from each participating hospital that will receive Vit-D medication (1500 IU to 3500 IU ) per day for 8 consecutive months up to 10 months. in addition to the experimental treatment, this group will receive the traditional treatment of hydroxyurea, Folic acid, pain killer plus regular blood transfusion with a dose de-escalation methods till efficacy of experimental treatment proved.
50 patients from each participating hospital that will receive Zinc supplements (15 mg to 50 mg ) per day for 8 consecutive months up to 10 months. in addition to the experimental treatment, this group will receive the traditional treatment of hydroxyurea, Folic acid, pain killer plus regular blood transfusion with a dose de-escalation methods till efficacy of experimental treatment proved.
50 patients from each participating hospital that will receive Simvastatin orally (20 mg to 40 mg ) per day for 8 consecutive months up to 10 months. in addition to the experimental treatment, this group will receive the traditional treatment of hydroxyurea, Folic acid, pain killer plus regular blood transfusion with a dose de-escalation methods till efficacy of experimental treatment proved.
50 patients from each participating hospital that will receive the ordinary treatment of Hydroxyurea (20 mg/kg/day) with monitoring blood count every 2 weeks maximum daily dose: (40 mg/kg/day) for 8 consecutive months up to 10 months.
Folic Acid dose of 0.5 to 1 mg daily for 3 to 4 weeks until definite hematologic response
Morphine medication as a pain killer is administered, if Patient weight \<50 kg: Opioid naïve: Initial: 0.05 mg/kg/dose; usual maximum initial dose: 1 to 2 mg/dose.
Regular blood transfusion session based on patient hematological profile starts from one session every 2 weeks.
Faculty of medicine, Beni-suef univeristy - Beni-Seuf university hospital
Banī Suwayf, Egypt
Faculty of Pharmacy, Beni-Suef university
Banī Suwayf, Egypt
Health insurance hospital
Banī Suwayf, Egypt
Maternity and Children hospital
Mecca, Saudi Arabia
C-reactive protein mg/L
C-reactive protein milligrams per deciliter
Time frame: 10 months
Hematocrit %
Hematocrit level in percentage value
Time frame: 10 months
Fibrinogen mg/dl
Fibrinogen concentration in milligrams per deciliter
Time frame: 10 months
Total cholesterol Mg/dl
Total cholesterol milligrams per deciliter
Time frame: 10 months
HDL cholesterol Mg/dl
HDL cholesterol milligrams per deciliter
Time frame: 10 months
LDL cholesterol Mg/dl
LDL cholesterol milligrams per deciliter
Time frame: 10 months
Triglycerides Mg/dl
Triglycerides milligrams per deciliter
Time frame: 10 months
leukocytes count μl
leukocytes in microliter
Time frame: 10 months
hemoglobin (Hbg) g/dL
hemoglobin (Hbg) gram/deciliter
Time frame: 10 months
White blood cells count
White blood cells count in a cubic milliliter of blood
Time frame: 10 months
Lactic acid dehydrogenase U/L
Lactic acid dehydrogenase unit per litter
Time frame: 10 months
Reticulocyte count %
Reticulocyte count percentage
Time frame: 10 months
Red blood cell (erythrocyte ) sedimentation rate mm/hr
erythrocyte sedimentation rate in millimeters (mm) per one hour(hr)
Time frame: 10 months
lymphocyte count µL
lymphocyte count in 1 microliter (µL) of blood
Time frame: 10 months
Granulocyte absolute count cells/microliter
Granulocyte cells numbers in microliter
Time frame: 10 months
Granulocytes,percentage (GR, pct)
percentage of white blood cells with granules in percentage
Time frame: 10 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.